Literature DB >> 26371437

Tuning the relaxation rates of dual-mode T(1)/T(2) nanoparticle contrast agents: a study into the ideal system.

Natasha A Keasberry1, Manuel Bañobre-López, Christopher Wood, Graeme J Stasiuk, Juan Gallo, Nicholas J Long.   

Abstract

Magnetic resonance imaging (MRI) is an excellent imaging modality. However the low sensitivity of the technique poses a challenge to achieving an accurate image of function at the molecular level. To overcome this, contrast agents are used; typically gadolinium based agents for T1 weighted imaging, or iron oxide based agents for T2 imaging. Traditionally, only one imaging mode is used per diagnosis although several physiological situations are known to interfere with the signal induced by the contrast agents in each individual imaging mode acquisition. Recently, the combination of both T1 and T2 imaging capabilities into a single platform has emerged as a tool to reduce uncertainties in MR image analysis. To date, contradicting reports on the effect on the contrast of the coupling of a T1 and T2 agent have hampered the application of these specialised probes. Herein, we present a systematic experimental study on a range of gadolinium-labelled magnetite nanoparticles envisioned to bring some light into the mechanism of interaction between T1 and T2 components, and advance towards the design of efficient (dual) T1 and T2 MRI probes. Unexpected behaviours observed in some of the constructs will be discussed. In this study, we demonstrate that the relaxivity of such multimodal probes can be rationally tuned to obtain unmatched potentials in MR imaging, exemplified by preparation of the magnetite-based nanoparticle with the highest T2 relaxivity described to date.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26371437     DOI: 10.1039/c5nr04400f

Source DB:  PubMed          Journal:  Nanoscale        ISSN: 2040-3364            Impact factor:   7.790


  8 in total

Review 1.  Biological effects of MRI contrast agents: gadolinium retention, potential mechanisms and a role for phosphorus.

Authors:  Joel Garcia; Stephen Z Liu; Angelique Y Louie
Journal:  Philos Trans A Math Phys Eng Sci       Date:  2017-11-28       Impact factor: 4.226

2.  Gadolinium-labelled iron/iron oxide core/shell nanoparticles as T 1-T 2 contrast agent for magnetic resonance imaging.

Authors:  Kaili Wang; Lu An; Qiwei Tian; Jiaomin Lin; Shiping Yang
Journal:  RSC Adv       Date:  2018-07-26       Impact factor: 4.036

3.  T1-T2 molecular magnetic resonance imaging of renal carcinoma cells based on nano-contrast agents.

Authors:  Jingjing Li; Jia You; Chen Wu; Yue Dai; Meilin Shi; Lina Dong; Kai Xu
Journal:  Int J Nanomedicine       Date:  2018-08-10

4.  Targeted Molecular Iron Oxide Contrast Agents for Imaging Atherosclerotic Plaque.

Authors:  Rhiannon J Evans; Begoña Lavin; Alkystis Phinikaridou; Kok Yean Chooi; Zahra Mohri; Eunice Wong; Joseph J Boyle; Rob Krams; René Botnar; Nicholas J Long
Journal:  Nanotheranostics       Date:  2020-05-30

5.  Improving Longitudinal Transversal Relaxation Of Gadolinium Chelate Using Silica Coating Magnetite Nanoparticles.

Authors:  Kai Xu; Heng Liu; Junfeng Zhang; Haipeng Tong; Zhenghuan Zhao; Weiguo Zhang
Journal:  Int J Nanomedicine       Date:  2019-09-26

6.  pH-responsive theranostic nanocomposites as synergistically enhancing positive and negative magnetic resonance imaging contrast agents.

Authors:  Xi Huang; Yaping Yuan; Weiwei Ruan; Lianhua Liu; Maili Liu; Shizhen Chen; Xin Zhou
Journal:  J Nanobiotechnology       Date:  2018-03-27       Impact factor: 10.435

Review 7.  Smart magnetic resonance imaging-based theranostics for cancer.

Authors:  Beatriz Brito; Thomas W Price; Juan Gallo; Manuel Bañobre-López; Graeme J Stasiuk
Journal:  Theranostics       Date:  2021-08-07       Impact factor: 11.556

Review 8.  Magnetic Solid Nanoparticles and Their Counterparts: Recent Advances towards Cancer Theranostics.

Authors:  Mónica Cerqueira; Efres Belmonte-Reche; Juan Gallo; Fátima Baltazar; Manuel Bañobre-López
Journal:  Pharmaceutics       Date:  2022-02-25       Impact factor: 6.321

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.